Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Teva, Blackstone Life Sciences Enter $400M Funding Agreement for Duvakitug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Teva, Blackstone Life Sciences Enter $400M Funding Agreement for Duvakitug

Duvakitug is currently in phase 3 trials for ulcerative colitis and Crohn’s disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and funds managed by Blackstone Life Sciences, entered a $400 million strategic funding agreement spread across four years to support the clinical development of duvakitug. Under the terms of the agreement, Blackstone will be eligible for regulatory and commercial milestones as well as royalties on duvakitug worldwide sales.

Duvakitug is a human monoclonal antibody targeting TL1A, a target with the potential for broad therapeutic application across multiple indications. Under a separate and independent agreement announced in 2023, Teva is co-developing and, subject to regulatory approval, will be co-commercializing this asset with Sanofi. 

Duvakitug is currently in phase 3 clinical studies for the treatment of ulcerative colitis and Crohn’s disease. Both companies recently announced phase 2b duvakitug maintenance data demonstrating clinically meaningful durable efficacy in UC and CD.

“Today’s announcement highlights how we are turning strategy into action under Pivot to Growth,” said Evan Lippman, Executive Vice President, Business Development, Teva. “By pursuing disciplined, capital-efficient partnerships, we are accelerating pipeline advancement while maintaining financial strength. This is the model we will continue using to build a more innovative, resilient, and growth-oriented Teva.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics